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Available online 10 November 2017Background:A potential link between increase in total cholesterol and triglycerides and clinical improvement has
been observed during antipsychotic drug treatment in chronic schizophrenia patients, possibly due to drug re-
lated effects on lipid biosynthesis. We examinedwhether changes in serum lipids are associatedwith alleviation
of psychosis symptoms after one year of antipsychotic drug treatment in a cohort offirst-episode psychosis (FEP)
patients.
Methods: A total of 132 non-affective antipsychotic-treated FEP patients were included through the Norwegian
Thematically Organized Psychosis (TOP) project. Data on antipsychotic usage, serum lipids (total cholesterol,
high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol and triglycerides (TG)),
body mass index (BMI) and clinical state were obtained at baseline and after 12 months. The Positive and Neg-
ative Syndrome Scale (PANSS) was used to assess psychotic symptoms. Mixed-effects models were employed
to examine the relationship between serum lipids and psychotic symptoms while controlling for potential con-
founders including BMI.
Results: An increase in HDL during one year of antipsychotic treatment was associated with reduction in PANSS
negative subscores (B=−0.48, p= 0.03). This relationship was not affected by concurrent change in BMI (ad-
justed HDL: B=−0.54, p=0.02). No significant associationswere found between serum lipids, BMI and PANSS
positive subscores.
Conclusion:We found that an increase in HDL level during antipsychotic treatment is associated with improve-
ment in negative symptoms in FEP. These findings warrant further investigation to clarify the interaction be-
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an open access article under1. Introduction
Metabolic disturbances such as obesity and dyslipidemia are com-
mon in schizophrenia (Allison et al., 1999; Mitchell et al., 2013;
Vancampfort et al., 2013). Thesemetabolic abnormalitiesmay be caused
by environmental factors, but can also be intrinsic to the illness itself
(Mitchell et al., 2013; Vancampfort et al., 2013). Indeed, dyslipidemia
has been observed in antipsychotic-naive and in first-episode psychosis
(FEP) patients (Chen et al., 2013; De Hert et al., 2006; Enez Darcin et al.,
2014; Fleischhacker et al., 2013; Kaddurah-Daouk et al., 2012; Misiak et
al., 2016; Saari et al., 2004; Thakore, 2004; Verma et al., 2009;Wu et al.,
2013; Zhai et al., 2017). In linewith thesefindings, there is also evidence
of overlapping genetic markers between disturbed lipid metabolism
and schizophrenia (Andreassen et al., 2013). Additional findings ofthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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(Bernstein et al., 2015; Davis et al., 2016; Mighdoll et al., 2015) also in-
dicate an involvement of lipids, as cholesterol is crucial for myelin for-
mation and functioning (Dietschy and Turley, 2004; Saher et al., 2005;
Verheijen et al., 2003).
Themetabolic effects ofmany antipsychotic drugs further illuminate
the possible link between lipid factors and schizophrenia. It is well
known that treatment with antipsychotics may lead to weight gain
and dyslipidemia (Goncalves et al., 2015; Musil et al., 2015; Young et
al., 2015). Weight gain, mainly caused by enhanced appetite and food
intake, may indirectly increase lipid levels, but it has also been shown
that dyslipidemia can occur independently of weight gain in antipsy-
chotic treated patients (Birkenaes et al., 2008; Lally et al., 2013;
Procyshyn et al., 2007). Although antipsychotic-related metabolic
changes have been associated with negative health consequences (De
Hert et al., 2011; Mitchell et al., 2013; Nasrallah et al., 2015;
Newcomer, 2005), there are also several studies that report a positive
link between treatment-related weight gain and improvement in psy-
chosis (Bai et al., 2006; Czobor et al., 2002; Gupta et al., 1999; Hermes
et al., 2011; Lamberti et al., 1992; Lane et al., 2003; Leadbetter et al.,
1992; Meltzer et al., 2003; Sharma et al., 2014). Similarly, treatment-re-
lated increases in serum triglycerides (TG) have been associated with
improvement in overall psychotic symptoms, and with a reduction in
positive symptoms (Atmaca et al., 2003; Lally et al., 2013; Pande et al.,
2002). There are also reports of an association between an increase in
TG and/or total cholesterol, and improvement in negative symptoms
(Chen et al., 2014; Procyshyn et al., 2007) and in cognitive symptoms
(Krakowski and Czobor, 2011). Recent advances in lipidomics research,
moreover, have linked changes in cell membrane lipid profiles to treat-
ment response, signifying the multifaceted role of lipids in psychosis
(Kaddurah-Daouk et al., 2012; Tessier et al., 2016). Nevertheless, thena-
ture of these associations is not fully clarified, as prior studies have
mainly involved chronic patients in whom the long-term effect of
poor lifestyle and multiple drug exposures may be difficult to
disentangle.
The main objective of the present study was to explore the relation-
ship between serum lipids and symptom relief in FEP patients during
their first year of antipsychotic treatment. Our main hypothesis was
that an increase in serum lipids during antipsychotic treatment would
be associated with improvement of psychosis-related symptoms, even
after controlling for potential confounders including changes in body
mass index (BMI). To test our hypothesis, we used data from a longitu-
dinal sample of FEP patientswhere data regarding serum lipids, BMI and
clinical state (i.e. positive and negative symptoms) at baseline and after
12 months of treatment were obtained.
2. Materials and methods
2.1. Study design
The present study is a prospective longitudinal study with a natural-
istic design, with patients recruited at their first treatment for a psy-
chotic disorder from inpatient and outpatient psychiatric units in the
catchment areas of the major hospitals in Oslo, Norway, as part of the
larger Thematically Organized Psychosis (TOP) study (http://www.
med.uio.no/norment/english/). The Regional Ethics Committee and
The Norwegian Data Inspectorate approved the study.
2.2. Patients
One hundred and thirty-two FEP patients were included in the pres-
ent study (see Fig. 1). The inclusion criteria followed the general inclu-
sion criteria for the TOP study: (1) age 18 to 65 years, (2) meeting the
diagnostic criteria for a broad schizophrenia spectrumpsychosis accord-
ing to Diagnostic and StructuralManual ofMental Disorders, fourth ver-
sion (DSM-IV, American Psychiatric Association, 2000), (3) no headtrauma, neurological or other medical disorder that could influence
CNS functioning, and (4) IQ over 70. The specific inclusion criteria for
this longitudinal study was that the patient had not previously received
adequate treatment for their psychotic disorder. Adequate treatment
was defined as antipsychotic medication in doses over 1 Defined Daily
Dosage (DDD) for N12 weeks or shorter if this treatment was followed
by symptomatic remission; “first episode psychosis”. DDD is the as-
sumed average maintenance dose per day for a drug used for its main
indication in adults (https://www.whocc.no/ddd/definition_and_
general_considera/). In general, the patients were recruited in the
early phases of treatment. However, some individuals were too psy-
chotic to give informed consent at an early stage and patients could
thus give consent to enter the study up to 52 weeks after start of first
treatment (for details see Simonsen et al., 2017). For the purposes of
the analyses in the current paper we did not include patients who (1)
were not using any antipsychotics at baseline as well as at follow-up,
and (2) participants treated with cholesterol-lowering medications
(statins and fibrates).
The distribution of diagnoseswas as follows:N=87 (66%)with a di-
agnosis of schizophrenia,N=5(4%) schizophreniformdisorder,N=16
(12%) schizoaffective disorder andN=24 (18%) psychotic disorder not
otherwise specified (psychosis NOS).
2.3. Clinical assessments
Sociodemographic history (including age, gender, ethnicity, edu-
cation), smoking, alcohol consumption, diet, exercise habits, dura-
tion of untreated psychosis (DUP), hospitalization, antipsychotic
medication, and use of cholesterol-lowering medication were ob-
tained through structured interviews. The ethnicity of patients was
categorized as Caucasian or non-Caucasian. All patients were diag-
nosed with the Structural Clinical Interview for DSM-IV (SCID)
(First et al., 1996). Inter-rater reliability was good, with an overall
kappa score of 0.77 (95% CI: 0.60–0.94). Psychotic and other related
symptoms were assessed using The Positive and Negative Syndrome
Scale (PANSS) (Kay et al., 1987), we report the means for a five-fac-
tor model (Wallwork et al., 2012). Depression was assessed with the
Calgary Depression Scale for Schizophrenia (CDSS) (Addington et al.,
1992). The extent of alcohol use was measured with The Alcohol Use
Disorders Identification Test (AUDIT) (Saunders et al., 1993). Diet
and exercise habits were assessed at inclusion and at 12 months by
interviews. The patients were asked to describe their eating habits
as healthy, moderately healthy or unhealthy. This variable was
then dichotomized into “similar or poorer diet” (including patients
who did not change their diet habits from inclusion to 12 months,
as well as patients who reported a poorer diet at 12 months) and
“better diet” (consisting of patients who reported a beneficial change
in diet). Exercise was also initially assessed as light, moderate or
hard, and then dichotomized into “similar or reduced exercise” and
“increased exercise” at 12 months. Our rationale for dichotomizing
diet and exercise was that we were primarily interested in the
change in these variables, as they would reflect improvement or de-
cline in lifestyle.
2.4. Use of antipsychotic medication
Information about current and previous use of antipsychotics was
obtained through interviewswith the patients combinedwith prescrip-
tion data from themedical charts. All participants used one or more an-
tipsychotics at least once during the study period (see Supplementary
Tables 1–4, for information concerning antipsychotic and non-psycho-
tropic drug use). For the purpose of this study, where our main goal
was to investigate if serum lipid changes during antipsychotic drug
therapy were related to improvement in psychosis, we defined treat-
ment with any type of antipsychotic agent throughout the study period
as continuous antipsychotic use (n = 100; 76%). In contrast, treatment
Fig. 1. Participants flow chart.
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(n=32; 24%), was defined as intermittent antipsychotic use, see Table
1 for details. Since the number of patients using the same antipsychotic
agent asmonotherapy at both time pointswas low (Table 1), we did not
have the statistical power to perform subgroup analyses for the differ-
ent drugs.
Compliance was checked by measuring antipsychotic drug
levels in serum samples analyzed by standard therapeutic drug
monitoring methods at Diakonhjemmet Hospital, Oslo, Norway
(Solberg et al., 2016). Since antipsychotic drug levels give informa-
tion on the drug treatment at one particular point in time, which in
the present study did not necessarily reflect the drug treatment for
the whole study period, the drug levels were not included in the
main analyses, but this information was used to exclude non-
adherent patients.
2.5. Metabolic parameters
2.5.1. Serum lipid measurements
Blood was sampled in the morning after overnight fasting. Choles-
terol (total cholesterol, HDL, LDL) and TG were analyzed at the Depart-
ment of Clinical Chemistry at Oslo University Hospital with standard
enzymatic methods from Roche Diagnostics Norge AS, Oslo, Norway.
Data on serum lipids are reported in Table 2.2.5.2. BMI measurement
All participants were weighed on calibrated digital weights under
equal conditions and height was measured with standard methods.
Body mass index (BMI) was calculated according to the standard for-
mula: BMI = weight (in kilograms) divided by height (in meters
squared) (kg/m2).2.6. Statistical analysis
All statistical analyses were performed using SPSS version 22 (SPSS
Inc., Chicago, IL, USA/IBM, NewYork, USA). For the comparison of demo-
graphic and clinical characteristics, chi-squared test and t-tests were
used. Paired t-tests were used to examine the change in serum lipid
levels, BMI and PANSS positive and negative subscores during the fol-
low-up period. Pearson correlation coefficients were used to examine
the correlation between serum lipid levels and BMI.Multivariate regres-
sion analyses controlling for age, gender and continuous vs. intermittent
antipsychotic use were applied to examine the relationship between
metabolic variables and outcome measurements at baseline and after
12 months. Two-sided tests were employed in all analyses, and the sig-
nificance level was set to p ≤ 0.05.
Linear mixed effects models were applied to investigate the associa-
tion between change in PANSS positive and negative subscores and
Table 1
Demographic and treatment characteristics of the FEP sample.
Characteristics
Age (years), mean (SD) 26.7 (7.6)
Gender (male), n (%) 85 (64.4)
Ethnicity (Caucasian), n (%) 87 (65.9)
Education (years), mean (SD) 12.9 (2.8)
Change in diet (“better diet”)a, n (%) 20 (15.2)
Change in exercise (“increased exercise “)b, n (%) 21 (15.9)
Smoking (daily), n (%) 60 (45.5)
Alcohol use (AUDIT), mean (SD) 7.3 (7.6)
DUP (weeks), median (range) 40.0 (1–1040)
Hospitalization (at inclusion), n (%) 30 (22.7)
Antipsychotic treatment
Continuous antipsychotic usec, n (%) 100 (76)
Intermittent antipsychotic used, n (%) 32 (24)
Typical antipsychoticse, n (%) 16 (16)
Atypical antipsychotics, n (%) 116 (88)
Monotherapyf, n (%) 34 (26)
Polypharmacyg, n (%) 41 (31)
SD= standard deviation, n = number of subjects, % = percentage, AUDIT = Alcohol Use
Disorder Identification Test, DUP = duration of untreated psychosis.
a Diet was dichotomized into “similar or poorer diet” (including patients who did not
change their diet habits from inclusion to 12 months, as well as patients who reported a
poorer diet at 12months) and “better diet” (consisting of patients who reported a benefi-
cial change in diet).
b Exercisewas dichotomized into “similar or reduced exercise” (including patients who
did not change their exercise habits from inclusion to 12 months, as well as patients who
reported a reduced exercise at 12months) and “increased exercise” (consisting of patients
who reported increased exercise at 12 months).
c Continuous antipsychotic use was defined as use of any type of antipsychotic agent
throughout the study period.
d Intermittent antipsychotic use was defined as use of any type of antipsychotic agent,
either at baseline or at 12 months.
e All typical antipsychotic agents were used in combination with atypical agents.
f Monotherapy with the same antipsychotic agent at baseline and at 12 months, n:
olanzapine 15, aripiprazole 7, quetiapine 4, risperidone (tablet or injection) 3, ziprasidon
3, and paliperidone 1.
g Polypharmacy was defined as using multiple antipsychotic agents either (or both) at
baseline and at 12 months.
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BMI) from baseline to one year follow-up. In this procedure, both
PANSS positive and negative subscores were investigated in separate
models along with each metabolic parameter (total cholesterol, HDL,
LDL, TG and BMI). The PANSS subscores were defined as dependent fac-
tors, while time (baseline and 12 months), age, gender, continuous vs.
intermittent antipsychotic use, serum lipid levels (total cholesterol,
HDL, LDL, TG) and BMI were defined as fixed factors (independent var-
iables). Time was considered a repeated factor with compound covari-
ance. The final model was chosen based on the information criteria
(Akaike information criterion). Preliminary analyses were conducted
to ensure assumptions of normality, linearity, multicollinearity andTable 2
Paired t-tests examining the change in clinical characteristics from baseline to 12 months.
n Baseline 12 m
mean (SD) mea
Psychotic symptoms
Total PANSS scores 129 63.2 (13.9) 55.2
PANSS positive subscores 131 2.6 (1.0) 2.1
PANSS negative subscores 132 2.2 (1.0) 2.0
Metabolic parameters
Total cholesterol 99 4.90 (0.97) 4.92
HDL (mmol/L) 90 1.39 (0.40) 1.32
LDL (mmol/L) 86 2.99 (0.82) 3.08
Ln TG (mmol/L) 89 0.15 (0.55) 0.20
BMI (kg/m2) 112 24.9 (4.3) 26.3
n = total number of subjects with both baseline and 12 months data, PANSS = Positive and N
lipoprotein cholesterol, Ln TG= ln of triglycerides, BMI=bodymass index, SD= standard devi
P-values are obtained from paired t-tests.homoscedasticity. Serum TG values were ln-transformed after inspec-
tion of residuals. Due to issues with multicollinearity, we did not enter
all the lipids in the samemixedmodel analysis. Therewere no problems
with linearity or homoscedasticity.
Missing variables were treated pairwise. Preliminary analyses
showed that the missing variables were randomly distributed (Little's
MCAR test: chi-square = 463.54, df = 440, and p = 0.21) and that
there were no significant differences in sociodemography, illness-re-
lated factors or antipsychotic usage between the patientswith complete
lipid datasets and the oneswithmissing lipid data. To further ensure the
validity of the results we reran themixedmodel analyses including only
subjects with full dataset (total cholesterol n = 99; HDL n = 90; LDL n
= 86; ln TG n = 89; BMI n = 112).
3. Results
One hundred and thirty-two FEP patients participated, of whom 85
(64%) were males and 87 (66%) were Caucasians. Mean age was 26.7
(SD = 7.6) years and median DUP 40.0 (range 1–1040) weeks. See
Table 1.
3.1. Changes in serum lipid levels and BMI
There was a statistically significant decrease of 0.07 mmol/L (SD =
0.27) in mean HDL from baseline (1.39 mmol/L; SD = 0.38) to
12 months (1.32 mmol/L; SD = 0.37) at the group level (p = 0.02);
49 subjects (54%) experienced a decrease and 41 subjects (46%) an in-
crease in their HDL levels (Table 2). There were no significant changes
in serum total cholesterol, LDL or ln TG (Table 2). Also, there were no
significant differences in the direction of lipid change between continu-
ous vs. intermittent antipsychotic use (data not shown).
Paired sample t-test showed that mean BMI increased significantly
from 25.0 (SD = 4.2) to 26.3 (SD = 4.7) during the follow-up period
(p b 0.001) (Table 2). Eighty-three patients (74%) with BMI measure-
ments experienced weight gain. Forty-four (39%) out of these cases ex-
perienced a clinically significant increase in BMI, i.e. ≥7% of BMI at
baseline. Twenty-nine patients (26%) displayed a reduction in BMI, of
whom 20 subjects (69%) were using antipsychotic medication during
the entire study period. There were no significant differences in direc-
tion of weight change between patients with continuous antipsychotic
use vs. patients with intermittent use (chi-square (1, N = 112) =
1.71, p = 0.19).
3.2. Relationship between serum lipids and BMI
Pearson correlation coefficients showed that changes in total choles-
terol levels were correlated with changes in HDL (r = 0.21, p = 0.05),
LDL (r = 0.64, p b 0.001), ln TG (r = 0.22, p = 0.04) and BMI (r =onths Δ t (df) p-value
n (SD) mean (SD)
(14.7) −8.1 (14.0) −6.6 (128) b0.001
(1.0) −0.5 (1.1) −5.3 (130) b0.001
(0.9) −0.2 (0.9) −2.2 (130) 0.03
(0.96) 0.02 (0.72) 0.29 (98) 0.77
(0.37) −0.07 (0.27) −2.39 (89) 0.02
(1.27) 0.16 (1.06) 1.44 (85) 0.15
(0.52) 0.07 (0.55) 1.15 (88) 0.25
(4.7) 1.4 (2.5) 5.83 (111) b0.001
egative Syndrome Scale, HDL = high-density lipoprotein cholesterol, LDL = low-density
ation,Δ=change from baseline to one year follow-up, t= t-test, df=degrees of freedom.
257P.B. Gjerde et al. / Schizophrenia Research 197 (2018) 253–2600.22, p= 0.04). Ln TG levels were correlated with changes in HDL (r=
−0.28, p = 0.01) and LDL (r = 0.33, p = 0.002) levels.
3.3. Relationship between serum lipid levels, BMI and psychotic symptoms
At baseline, multivariate linear regression analyses showed a nega-
tive association between HDL level and PANSS negative subscores
when controlling for age, gender and continuous vs. intermittent anti-
psychotic use (B = −0.67, p = 0.02) (Supplementary Table 5). At
12months, therewere no significant associations between serum lipids,
BMI, and PANSS positive and negative subscores (Supplementary Table
5).
The mixed effects model demonstrated a significant association be-
tween an increase in HDL and a decrease in PANSS negative subscores
after one year (B =−0.48, p = 0.03) when controlling for age, gender
and continuous vs. intermittent antipsychotic use (Table 3). Similar re-
sults were found when we analyzed with complete lipid dataset (B:
−0.62, p = 0.01). Furthermore, the association between change in
HDL and change in negative symptoms remained significant after con-
trolling for BMI change (B=−0.54, p=0.02) (Table 4). No significant
associations were found between total cholesterol, LDL, ln TG, BMI and
PANSS positive and negative subscores (Table 3).
3.4. Post hoc analyses examining the negative association betweenHDL and
PANSS negative subscores
Group comparison between patients with an increase in HDL levels
(n=41, 46%) versus thosewith a decrease (n=49, 54%) during the fol-
low-up period displayed no significant differences in sociodemographic
or illness-related factors except that the HDL increase group had higher
mean PANSS negative subscore at baseline, 2.5 (SD= 1.1) vs. 2.0 (SD=
1.0) (p=0.04) and a highermeanAUDIT score at 12months, 8.8 (SD=
7.0) vs. 5.1 (SD = 5.2) (p = 0.01), respectively (Supplementary Table
6).
Post hoc mixed model analyses showed that neither illness (includ-
ing diagnosis subgroup, DUP, hospitalization, concurrent changes in
PANSS positive subscores and CDSS scores) nor lifestyle-related factors
(including smoking, alcohol use, changes in diet and changes in exer-
cise) significantly influenced the relationship between HDL and PANSS
negative subscores (Supplementary Table 7).
4. Discussion
The main finding of the present one year follow-up study of FEP pa-
tients was that increase in HDL levels during one year of antipsychotic
treatmentwas significantly associatedwith a reduction in negative psy-
chotic symptoms (i.e. PANSS negative subscores), an association that
remained significant after controlling for potential confounders, includ-
ing demographic variables, lifestyle factors, and BMI.
The important role of cholesterol (total, HDL, and LDL) for human
health has been known for decades. Patients with schizophrenia have
markedly increased prevalence of metabolic abnormalities includingTable 3
Mixed models examining the association between change in metabolic parameters and PANSS
PANSS positive subscores
Coefficient 95% CI p-v
Total cholesterol 0.10 (−0.05, 0.25) 0.1
HDL 0.33 (−0.09, 0.75) 0.1
LDL 0.09 (−0.04, 0.23) 0.1
Ln TG 0.07 (−0.18, 0.33) 0.5
BMI −0.01 (−0.04, 0.02) 0.4
PANSS = Positive and Negative Syndrome Scale, HDL = high-density lipoprotein cholesterol,
index, CI = confidence interval. Analyzed with mixed effects model and adjusted for covariate
antipsychotic use (use of any type of antipsychotic agent throughout the study period) vs. interm
months).dyslipidemia, and several meta-analyses have demonstrated hypertri-
glyceridemia and low HDL-cholesterol in chronic schizophrenia
(Mitchell et al., 2013; Vancampfort et al., 2013). More recently, such
low HDL levels have also been reported in FEP, including antipsychotic
drug-naïve patients (Enez Darcin et al., 2014; Fleischhacker et al.,
2013; Misiak et al., 2016; Wu et al., 2013; Zhai et al., 2017) and even
subjects with prodromal symptoms only, i.e. at high risk of developing
psychosis (Cordes et al., 2016). Thesefindings suggest that a suboptimal
level of HDL cholesterol serves as an unfavorable lipid marker in early
psychosis.
It is, therefore, interesting that we demonstrate a significant associ-
ation between an increase in HDL level and a reduction in PANSS nega-
tive subscores during one year of antipsychotic treatment in FEP
patients. Usually, the lipid disturbances in schizophrenia tend toworsen
with time, and multi-episode patients with schizophrenia have signifi-
cantly higher prevalence of abnormally low HDL cholesterol as com-
pared to FEP and antipsychotic naïve patients (Vancampfort et al.,
2013). We found on a group level that the mean HDL level decreased
following one year of antipsychotic treatment, which is in accordance
with the literature on medicated FEP (Correll et al., 2014; Wu et al.,
2013). Still, almost half of the FEP patients in our study experienced
an increase in HDL level. The reasons for this beneficial change in HDL
are uncertain, but they may be related to treatment effects (including
antipsychotic drugs) and changes in lifestyle and diet. As the different
antipsychotic agents have different effects on serum lipid levels, it
would have been interesting to examine the subgroups of antipsy-
chotics (e.g., olanzapine) that have previously been shown to have a
high tendency to cause dyslipidemia. However, due to the low number
of subjects treated with each of the antipsychotic agent throughout the
study period, we could not look specifically at the subgroups of drugs.
Our data do not prove any causal relationship between the increase
in HDL and decrease in negative symptoms in FEP patients. An interest-
ing but speculative theory is to consider HDL in serum as an indirect
proxy for cholesterol in the brain, where improved supply could play a
positive role in myelination. It has previously been indicated that pa-
tients with schizophrenia have reduced myelination in the CNS
(Bernstein et al., 2015; Davis et al., 2016; Mighdoll et al., 2015), and in
vivo MRI and animal studies have demonstrated pro-myelinating ef-
fects of antipsychotic drugs (Bartzokis et al., 2012, 2007; Ebdrup et al.,
2016; Xu et al., 2010) that in part could be related to their lipid-stimu-
lating effects (Cai et al., 2015; Steen et al., 2017). It is also possible that
genetic factors per se could influence lipid metabolism as a risk factor
for schizophrenia (Andreassen et al., 2013; Solberg et al., 2016). On
the other hand, the observed link between HDL and PANSS negative
subscores could represent an indirect effect of successful treatment
that reduces the negative symptoms, leading to subsequent changes in
lifestyle and diet improving HDL levels. The fact that the patients who
experienced an increase in HDL had lower HDL levels at baseline and
more pronounced negative symptoms could to some degree support
this. Nevertheless, it is worth mentioning that we found a similar link
between higher HDL levels and lower negative psychotic symptoms
also at baseline. Additionally, the patients who increased in HDL levelspositive and negative subscores trajectories from baseline to 12 months.
PANSS negative subscores
alue Coefficient 95% CI p-value
9 0.01 (−0.14, 0.16) 0.90
3 −0.48 (−0.90, −0.06) 0.03
7 0.03 (−0.10, 0.16) 0.68
6 0.15 (−0.10, 0.40) 0.23
5 −0.01 (−0.04, 0.03) 0.73
LDL = low-density lipoprotein cholesterol, Ln TG = ln of triglycerides, BMI = body mass
s age, gender, and antipsychotic use. Antipsychotic use was dichotomized into continuous
ittent antipsychotic use (use of any type of antipsychotic agent, either at baseline or at 12
Table 4
Mixedmodels examining the association between change inmetabolic parameters and PANSS positive andnegative subscores trajectories frombaseline to 12monthswhile controlling for
BMI.
PANSS positive subscores PANSS negative subscores
Coefficient 95% CI p-value Coefficient 95% CI p-value
Total cholesterol 0.14 (−0.02, 0.29) 0.09 0.02 (−0.14, 0.18) 0.81
HDL 0.36 (−0.09, 0.81) 0.12 −0.54 (−0.98, −0.09) 0.02
LDL 0.10 (−0.04, 0.23) 0.16 0.04 (−0.10, 0.17) 0.61
Ln TG 0.14 (−0.13, 0.40) 0.32 0.18 (−0.08, 0.44) 0.18
PANSS= Positive and Negative Syndrome Scale, HDL= high-density lipoprotein cholesterol, LDL= low-density lipoprotein cholesterol, Ln TG= ln of triglycerides, CI = confidence in-
terval. Analyzed with mixed effects model and adjusted for covariates age, gender, antipsychotic use and body mass index (BMI). Antipsychotic use was dichotomized into continuous
antipsychotic use (use of any type of antipsychotic agent throughout the study period) vs. intermittent antipsychotic use (use of any type of antipsychotic agent, either at baseline or
at 12 months).
258 P.B. Gjerde et al. / Schizophrenia Research 197 (2018) 253–260did not differ from those who decreased with respect to
sociodemographic, lifestyle- or illness-related factors, except for
reporting higher alcohol consumption at 12 months. Still, there was
no increase in alcohol use during the follow-up period as these patients
had similar levels of alcohol consumption at baseline. In addition, it is
unlikely that higher alcohol consumption could explain why these pa-
tients improved in negative psychotic symptoms as high alcohol con-
sumption is often related to more psychotic symptoms (Addington et
al., 2014).
Prior studies that have investigated the potential relationship be-
tween lipid changes and improvement of psychotic symptoms during
antipsychotic treatment have predominantly reported an association
between increase in serum TG levels and reduction in overall psychotic
symptoms and in positive symptoms (Atmaca et al., 2003; Lally et al.,
2013; Pande et al., 2002; Procyshyn et al., 2007) leading us to hypothe-
size that a similar relationship could also be found in our sample of FEP
patients. However, we did not observe such a relationship. One possible
explanation for this difference may be that the patients in prior studies
were often treated with clozapine, a drug reserved for patients with
treatment-resistant psychosis and recognized for its dyslipidemic po-
tential (Mitchell et al., 2013). In our sample (with only three clozapine
users), TG levels were not significantly altered during the follow-up pe-
riod. This may have impeded a potential relationship between TG levels
and psychotic symptoms.
Many studies have reported an association between treatment-re-
lated weight gain and improved clinical outcome in schizophrenia (Bai
et al., 2006; Basson et al., 2001; Bustillo et al., 1996; Czobor et al.,
2002; Hermes et al., 2011; Meltzer et al., 2003; Yang et al., 2014). We
did not observe such a link between increased bodyweight and reduced
psychotic symptoms, despite the fact that two thirds of our patients ex-
perienced an increase in BMI. Although BMI and serum lipids may be
correlated, we did not find a significant correlation between these two
metabolic variables. It should also be noted that these parameters may
be partly independent in patients treated with antipsychotic drugs
(Birkenaes et al., 2008; Kang and Lee, 2015; Lally et al., 2013;
Procyshyn et al., 2007).
The present study has limitations that require consideration. Be-
cause of the naturalistic study design there are many confounding fac-
tors, which cannot be controlled for. The dynamic nature of treatment
for schizophrenia with frequent changes in antipsychotic regimens dur-
ing the follow-up period is an important limitation. Furthermore, serum
lipids were missing for a number of patients, especially at 12 months.
We did, however, try to minimize the effect of these missing variables
by usingmixed effects models. Also, whenwe repeated the analyses in-
cluding only subjects with a complete dataset, similar results were
found. We did not provide structured assessments of intake of fish oil
and dietary seafood, or habitual amount of exercise, factors that may in-
fluence both the metabolic parameters and symptom levels. However,
we used self-report assessments of changes in diet and exercise habits
to partially control for these potential confounders in the mixed
model analyses. We also controlled for the effect of smoking, alcohol
use and education, which may be regarded as proxies for lifestylefactors. It is nevertheless possible that other factors not accounted for
could have influenced the results. Patients were receiving standard
treatment from the University Hospital and followed recent guidelines,
thus, the clinical change was not due to different quality of treatment.
In conclusion,we found that an increase inHDL level during antipsy-
chotics treatment was related to improvement in negative symptoms,
independent of weight change. To further elaborate the clinical signifi-
cance of the effects of antipsychotic treatment on lipid metabolism, suf-
ficiently powered longitudinal studies in drug-naïve patients are
needed.
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